Explore evolving ethical challenges of long-acting injectable antipsychotics, weighing relapse prevention against coercion, stigma, incentives, and racial equity in clinical practice.
|Articles|November 18, 2013
Mini-quiz: Schizophrenia and Cannabis Use Disorder
Listen
0:00 / 0:00
Key Takeaways
- Comorbid cannabis use disorder affects about one-quarter of patients diagnosed with schizophrenia.
- Cannabis can trigger an acute psychotic presentation, particularly in vulnerable individuals.
What percentage of patients with schizophrenia have a comorbid cannabis use disorder? Take the quiz and learn more.
Advertisement
What percentage of patients with schizophrenia have a comorbid cannabis use disorder?
For the answer,
Answer: D. 25% of patients with schizophrenia have a comorbid cannabis use disorder.
While research suggests that cannabis use can induce an acute psychotic state, there is controversy about whether it may precipitate psychotic disorders, such as schizophrenia. However, a history of cannabis misuse is more common in patients who are schizophrenic than in the general population.
For more on this topic,
Advertisement
Related to this article
Antipsychotic levels clarify adherence, guide dose escalation up to a point of futility, and offer more than pharmacogenetic testing, says Jonathan Meyer, MD.
How to interpret antipsychotic drug levels in schizophrenia: when labs mislead, when levels help adherence and toxicity checks, and why serial monitoring matters.
Therapeutic drug monitoring takes guesswork out of antipsychotic care—spotting nonadherence, guiding dose targets, and defining response thresholds and the “point of futility” in schizophrenia.
FDA approves monthly subcutaneous olanzapine LAI Weltruza, expanding schizophrenia treatment options and renewing debate on making long-acting injectables routine.
Athletes can feel the relief a substance gives them long before they can see what it costs. A composite case of cannabis use in a track athlete shows how to assess both.
Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.
Neurosterix advances NTX-253, an oral M4 PAM, into phase 2 for schizophrenia after phase 1 shows promising safety and pharmacokinetics.
Advertisement
Advertisement
Trending on Psychiatric Times
1
When Antidepressants Stop Working: Understanding Tachyphylaxis in Clinical Practice
2
What Do Patient-Level Studies Tell Us About Antidepressants and Suicide Risk?
3
Sleep Disruption and Alzheimer Disease: A Bidirectional, Treatable Relationship
4
The Psych Consult: TSH Testing in New-Onset Depression. An Endocrinologist’s Guidance for Psychiatrists
5